EyeGene Inc (185490) - Net Assets

Latest as of September 2025: ₩44.06 Billion KRW ≈ $29.86 Million USD

Based on the latest financial reports, EyeGene Inc (185490) has net assets worth ₩44.06 Billion KRW (≈ $29.86 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩56.60 Billion ≈ $38.36 Million USD) and total liabilities (₩12.55 Billion ≈ $8.50 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 185490 financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩44.06 Billion
% of Total Assets	77.83%
Annual Growth Rate	29.29%
5-Year Change	290.11%
10-Year Change	121.07%
Growth Volatility	222.48

EyeGene Inc - Net Assets Trend (2014–2024)

This chart illustrates how EyeGene Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is EyeGene Inc's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for EyeGene Inc (2014–2024)

The table below shows the annual net assets of EyeGene Inc from 2014 to 2024. For live valuation and market cap data, see market cap of EyeGene Inc.

Year	Net Assets	Change
2024-12-31	₩50.32 Billion ≈ $34.10 Million	-21.78%
2023-12-31	₩64.33 Billion ≈ $43.60 Million	-3.59%
2022-12-31	₩66.73 Billion ≈ $45.22 Million	-25.00%
2021-12-31	₩88.97 Billion ≈ $60.29 Million	+589.72%
2020-12-31	₩12.90 Billion ≈ $8.74 Million	-32.22%
2019-12-31	₩19.03 Billion ≈ $12.90 Million	-18.48%
2018-12-31	₩23.34 Billion ≈ $15.82 Million	-1.72%
2017-12-31	₩23.75 Billion ≈ $16.10 Million	+46.76%
2016-12-31	₩16.19 Billion ≈ $10.97 Million	-28.90%
2015-12-31	₩22.76 Billion ≈ $15.43 Million	+490.68%
2014-12-31	₩3.85 Billion ≈ $2.61 Million	--

Equity Component Analysis

This analysis shows how different components contribute to EyeGene Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 14494927944000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	₩13.51 Billion	26.86%
Other Components	₩198.55 Billion	394.56%
Total Equity	₩50.32 Billion	100.00%

EyeGene Inc Competitors by Market Cap

The table below lists competitors of EyeGene Inc ranked by their market capitalization.

Company	Market Cap
Petratherm Ltd AU:PTR	$29.26 Million
Amanet Management & Systems Ltd TA:AMAN	$29.28 Million
Micro-X Ltd AU:MX1	$29.28 Million
Tira Austenite Tbk JK:TIRA	$29.29 Million
Tubos Reunidos S.A MC:TRG	$29.23 Million
BuzzFeed Inc NASDAQ:BZFD	$29.21 Million
Horizon Space Acquisition I Corp. Ordinary Shares NASDAQ:HSPO	$29.21 Million
Wiscom KO:024070	$29.19 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in EyeGene Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 63,230,279,500 to 50,321,061,750, a change of -12,909,217,750 (-20.4%).
Net loss of 12,128,140,660 reduced equity.
New share issuances of 808,873,790 increased equity.
Other factors decreased equity by 1,589,950,880.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-12.13 Billion	-24.1%
Share Issuances	₩808.87 Million	+1.61%
Other Changes	₩-1.59 Billion	-3.16%
Total Change	₩-	-20.42%

Book Value vs Market Value Analysis

This analysis compares EyeGene Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.76x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 1.15x to 0.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩1231.29	₩1416.00	x
2017-12-31	₩1653.90	₩1416.00	x
2018-12-31	₩1621.25	₩1416.00	x
2019-12-31	₩1264.79	₩1416.00	x
2020-12-31	₩845.51	₩1416.00	x
2021-12-31	₩4155.60	₩1416.00	x
2022-12-31	₩3106.77	₩1416.00	x
2023-12-31	₩2339.28	₩1416.00	x
2024-12-31	₩1861.69	₩1416.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently EyeGene Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -24.10%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -361.41%
• Asset Turnover: 0.05x
• Equity Multiplier: 1.30x
Recent ROE (-24.10%) is above the historical average (-45.98%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	-75.92%	-1902.44%	0.03x	1.44x	₩-3.31 Billion
2015	-21.51%	-4552.80%	0.00x	1.07x	₩-7.17 Billion
2016	-51.10%	-3094.59%	0.01x	1.15x	₩-9.89 Billion
2017	-35.58%	-2807.29%	0.01x	1.27x	₩-10.83 Billion
2018	-25.31%	-290.27%	0.04x	2.32x	₩-8.24 Billion
2019	-45.93%	-205.88%	0.09x	2.49x	₩-10.64 Billion
2020	-115.22%	-441.90%	0.08x	3.44x	₩-16.15 Billion
2021	-38.85%	-1066.25%	0.03x	1.18x	₩-43.47 Billion
2022	-38.89%	-490.29%	0.07x	1.20x	₩-32.63 Billion
2023	-33.38%	-675.30%	0.04x	1.24x	₩-27.43 Billion
2024	-24.10%	-361.41%	0.05x	1.30x	₩-17.16 Billion

Industry Comparison

This section compares EyeGene Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $403,359,376,260
Average return on equity (ROE) among peers: 3.11%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
EyeGene Inc (185490)	₩44.06 Billion	-75.92%	0.28x	$29.23 Million
ORIENTBIO Inc. (002630)	$62.65 Billion	-31.14%	0.34x	$42.67 Million
Green Cross (005250)	$1.91 Trillion	2.89%	0.83x	$424.80 Million
Green Cross Holdings Preference Shares (005257)	$1.67 Trillion	10.22%	0.94x	$3.72 Million
Pharmicell (005690)	$76.66 Billion	10.78%	0.43x	$823.44 Million
GeneOne Life Science Inc (011000)	$33.79 Billion	0.00%	0.20x	$48.33 Million
HLB Co. Ltd (028300)	$21.19 Billion	0.00%	1.56x	$5.41 Billion
Daesung Microbiological Labs. Co. Ltd (036480)	$25.09 Billion	18.13%	0.29x	$18.95 Million
Seoulin Bioscience Co.Ltd (038070)	$59.71 Billion	14.88%	0.35x	$37.75 Million
Hyundai Bioscience Co. Ltd (048410)	$64.08 Billion	0.00%	2.13x	$937.21 Million
iNtRON Biotechnology Inc (048530)	$106.18 Billion	5.38%	0.33x	$74.45 Million

About EyeGene Inc

KQ:185490 Korea Biotechnology

Market Cap

$29.23 Million

₩43.14 Billion KRW

Market Cap Rank

#23786 Global

#1717 in Korea

Share Price

₩1416.00

Change (1 day)

-1.12%

52-Week Range

₩1193.00 - ₩3630.00

All Time High

₩50300.00